Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amanda Micklus

Principal Analyst, Datamonitor Healthcare

Connecticut, US
Amanda has been tracking corporate strategy and business development activities in the biopharma and medtech industries for more than 10 years. She is a principal analyst with Informa’s Datamonitor Healthcare where she researches and analyzes trends in corporate strategy and dealmaking, and compiles reports for clients. Amanda also writes trends pieces for Informa’s IN VIVO and START-UP publications, and contributes to Informa’s Strategic Transactions deals database, researching and writing analyses on individual biopharma and medtech transactions. Before joining Informa, Amanda spent five years at Purdue Pharma, working as a market research analyst and information searcher. She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library & Information Science from Long Island University.
Advertisement
Set Alert for Articles By Amanda Micklus

Latest From Amanda Micklus

Deals In Depth: March 2019

Alexion signed two $600m-plus alliances, with Zealand Pharma and Affibody, that made it into the top five deals by value. Thermo Fisher grew its capabilities in cell and gene therapy manufacturing by acquiring Brammer Bio for $1.7bn. A $3.5bn private placement by AstraZeneca boosted pharma financing.

Deals Market Intelligence

Deals Shaping The Medical Industry, May 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April 2019.

Deals Financing

Deals In Depth: February 2019

In a deal worth over $4bn, GlaxoSmithKline and Merck KGAA will develop M7824, which targets two immuno-suppressive pathways. Danaher paid $21.4bn for GE Healthcare's biopharma business. Biopharma funding was up while device financing decreased from the previous month.

Deals BioPharmaceutical

Investment Outlook For Cell And Gene Therapies Is Cautiously Optimistic

Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.

Regenerative Medicine Financing

Device/Diagnostics Quarterly Dealmaking Statistics, Q4 2018

Device fundraising in the fourth quarter totaled $1.5bn, a 42% decrease from Q3's $2.6bn. Q4 M&A activity reached $8.6bn. Q4 diagnostics financings brought in $1.2bn (a 32% increase over Q3) and M&As totaled $1.3bn (the second-highest quarter of the year).

Analysis Deals

Deals Shaping The Medical Industry, March 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2019.

Deals Financing
See All
Advertisement
UsernamePublicRestriction

Register